[On the problem of the cardiotoxicity of epirubicin-cisplatin].
Cardiotoxicity is supposed to be the most important limiting factor in chemotherapy with anthracycline derivatives. The left ventricular ejection fraction was measured several times by means of radionuclid - scintigraphy in 24 patients treated with epirubicin - cisplatinum. Pathologic values have been found only in 3 patients, but no correlation with age, cumulative dose or dose/m2 of body surface could be demonstrated.
Lechner
W
W
Universitäts-Klinik für Frauenheilkunde, Universitäts-Klinik für Nuklearmedizin, Innsbruck.
Zechmann
W
W
Mayr
P
P
Reider
W
W
Marth
C
C
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D002302:Cardiac Output / Q000187:drug effects; D009202:Cardiomyopathies / Q000139:chemically induced*; D002945:Cisplatin / Q000009:adverse effects; D004317:Doxorubicin / Q000009:adverse effects; D015251:Epirubicin; D005260:Female; D006801:Humans
D015251:Epirubicin; D004317:Doxorubicin; D002945:Cisplatin
Zur Frage der Kardiotoxizität von Epirubicin--Cisplatin.